Abdel-Aziz AK (2023) Advances in acute myeloid leukemia differentiation therapy: a critical review. Biochem Pharmacol 215:115709. https://doi.org/10.1016/j.bcp.2023.115709

Article  CAS  PubMed  Google Scholar 

Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988. https://doi.org/10.1073/pnas.0530291100

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anastasiadi Z, Lianos GD, Ignatiadou E, Harissis HV, Mitsis M (2017) Breast cancer in young women: an overview. Updates Surg 69(3):313–317. https://doi.org/10.1007/s13304-017-0424-1

Article  PubMed  Google Scholar 

Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L (2020) Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol 84:106535. https://doi.org/10.1016/j.intimp.2020.106535

Article  CAS  PubMed  Google Scholar 

Baumann P, Mandl-Weber S, Völkl A, Adam C, Bumeder I, Oduncu F, Schmidmaier R (2009) Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 8(2):366–375. https://doi.org/10.1158/1535-7163.Mct-08-0664

Article  CAS  PubMed  Google Scholar 

Boice AG, Lopez KE, Pandita RK, Parsons MJ, Charendoff CI, Charaka V, Carisey AF, Pandita TK, Bouchier-Hayes L (2022) Caspase-2 regulates S-phase cell cycle events to protect from DNA damage accumulation independent of apoptosis. Oncogene 41(2):204–219. https://doi.org/10.1038/s41388-021-02085-w

Article  CAS  PubMed  Google Scholar 

Brown KK, Spinelli JB, Asara JM, Toker A (2017) Adaptive reprogramming of De Novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer. Cancer Discov 7(4):391–399. https://doi.org/10.1158/2159-8290.Cd-16-0611

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brünner N, Boysen B, Rømer J, Spang-Thomsen M (1993) The nude mouse as an in vivo model for human breast cancer invasion and metastasis. Breast Cancer Res Treat 24(3):257–264. https://doi.org/10.1007/bf01833265

Article  PubMed  Google Scholar 

Buettner R, Morales C, Wu X, Sanchez JF, Li H, Melstrom LG, Rosen ST (2019) Leflunomide synergizes with gemcitabine in growth inhibition of PC cells and impairs c-Myc signaling through PIM kinase targeting. Mol Ther Oncolytics 14:149–158. https://doi.org/10.1016/j.omto.2019.04.006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cailleau R, Olivé M, Cruciger QV (1978) Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14(11):911–915. https://doi.org/10.1007/bf02616120

Article  CAS  PubMed  Google Scholar 

Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. https://doi.org/10.1038/nature11412

Article  CAS  Google Scholar 

Chen TL, Erlichman C (1992) Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells. Cancer Chemother Pharmacol 30(5):370–376. https://doi.org/10.1007/bf00689965

Article  CAS  PubMed  Google Scholar 

Cheng L, Wang H, Wang Z, Huang H, Zhuo D, Lin J (2020) Leflunomide inhibits proliferation and induces apoptosis via suppressing autophagy and PI3K/Akt signaling pathway in human bladder cancer cells. Drug Des Devel Ther 14:1897–1908. https://doi.org/10.2147/dddt.S252626

Article  CAS  PubMed  PubMed Central  Google Scholar 

Christian S, Merz C, Evans L, Gradl S, Seidel H, Friberg A, Eheim A, Lejeune P, Brzezinka K, Zimmermann K, Ferrara S, Meyer H, Lesche R, Stoeckigt D, Bauser M, Haegebarth A, Sykes DB, Scadden DT, Losman JA, Janzer A (2019) The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia 33(10):2403–2415. https://doi.org/10.1038/s41375-019-0461-5

Article  CAS  PubMed  Google Scholar 

Covarrubias L, Hernández-García D, Schnabel D, Salas-Vidal E, Castro-Obregón S (2008) Function of reactive oxygen species during animal development: passive or active? Dev Biol 320(1):1–11. https://doi.org/10.1016/j.ydbio.2008.04.041

Article  CAS  PubMed  Google Scholar 

de Forni M, Chabot GG, Armand JP, Fontana X, Recondo G, Domenge C, Carde P, Barbu M, Gouyette A (1993) Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients. Eur J Cancer 29(7):983–988. https://doi.org/10.1016/s0959-8049(05)80206-0

Article  Google Scholar 

Dorasamy MS, Choudhary B, Nellore K, Subramanya H, Wong PF (2017) Dihydroorotate dehydrogenase Inhibitors target c-Myc and arrest melanoma, myeloma and lymphoma cells at S-phase. J Cancer 8(15):3086–3098. https://doi.org/10.7150/jca.14835

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dorasamy MS, Ab A, Nellore K, Wong P-F (2019) Synergistic inhibition of melanoma xenografts by Brequinar sodium and doxorubicin. Biomed Pharmacother 110:29–36. https://doi.org/10.1016/j.biopha.2018.11.010

Article  CAS  PubMed  Google Scholar 

Espiau-Romera P, Courtois S, Parejo-Alonso B, Sancho P (2020) Molecular and metabolic subtypes correspondence for pancreatic ductal adenocarcinoma classification. J Clin Med. https://doi.org/10.3390/jcm9124128

Article  PubMed  PubMed Central  Google Scholar 

Fang J, Uchiumi T, Yagi M, Matsumoto S, Amamoto R, Takazaki S, Yamaza H, Nonaka K, Kang D (2013) Dihydro-orotate dehydrogenase is physically associated with the respiratory complex and its loss leads to mitochondrial dysfunction. Biosci Rep 33(2):e00021. https://doi.org/10.1042/bsr20120097

Article  PubMed  PubMed Central  Google Scholar 

Garrido-Castro AC, Lin NU, Polyak K (2019) Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov 9(2):176–198. https://doi.org/10.1158/2159-8290.Cd-18-1177

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giacinti C, Giordano A (2006) RB and cell cycle progression. Oncogene 25(38):5220–5227. https://doi.org/10.1038/sj.onc.1209615

Article  CAS  PubMed  Google Scholar 

Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, Waks AG, Keenan T, McAllister SS, Tolaney SM, Mittendorf EA, Guerriero JL (2021) The immunology of hormone receptor positive breast cancer. Front Immunol 12:674192. https://doi.org/10.3389/fimmu.2021.674192

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hadi NA, Mahmood RI, Al-Saffar AZ (2021) Evaluation of antioxidant enzyme activity in doxorubicin treated breast cancer patients in Iraq: a molecular and cytotoxic study. Gene Rep 24:101285. https://doi.org/10.1016/j.genrep.2021.101285

Article  CAS  Google Scholar 

Halliwell B (2011) Free radicals and antioxidants–quo vadis? Trends Pharmacol Sci 32(3):125–130. https://doi.org/10.1016/j.tips.2010.12.002

Article  CAS  PubMed  Google Scholar 

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70. https://doi.org/10.1016/s0092-8674(00)81683-9

Article  CAS  PubMed  Google Scholar 

Holliday DL, Speirs V (2011) Choosing the right cell line for breast cancer research. Breast Cancer Res 13(4):215. https://doi.org/10.1186/bcr2889

Article  PubMed  PubMed Central  Google Scholar 

Jori FP, Napolitano MA, Melone MA, Cipollaro M, Cascino A, Altucci L, Peluso G, Giordano A, Galderisi U (2005) Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J Cell Biochem 94(4):645–655. https://doi.org/10.1002/jcb.20315